BridgeBio Pharma
BBIO
247 hedge funds and large institutions have $6.69B invested in BridgeBio Pharma in 2023 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 88 increasing their positions, 77 reducing their positions, and 26 closing their positions.
108% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 26
58% more capital invested
Capital invested by funds: $4.24B → $6.69B (+$2.45B)
50% more funds holding in top 10
Funds holding in top 10: 10 → 15 (+5)
22% more call options, than puts
Call options by funds: $110M | Put options by funds: $90.1M
14% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 77
12% more funds holding
Funds holding: 220 → 247 (+27)
3.9% less ownership
Funds ownership: 99.16% → 95.26% (-3.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$69.2M |
| 2 |
Goldman Sachs
New York
|
+$55.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.8M |
| 4 |
BlackRock
New York
|
+$27.2M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$41.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$39.6M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$25.1M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$19M |
| 5 |
Renaissance Technologies
New York
|
-$15.4M |
BBIO Hedge Fund Activity: Q4 2023 in Review
247 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2023, worth a combined $6.69B — up 58% from $4.24B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new BBIO positions and 26 closed out — a net gain of 28 holders — while 88 added to existing stakes and 77 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $69.2M. The largest seller was HHLR Advisors, cutting an estimated $41.8M.
- 247 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2023, up from 220 in Q3 2023.
- Funds reported $6.69B of BridgeBio Pharma stock for Q4 2023, up 58% quarter-over-quarter.
- 54 funds opened new BridgeBio Pharma positions in Q4 2023 and 26 closed out, a net change of +28 holders.
- The largest BridgeBio Pharma buyer in Q4 2023 was Lord, Abbett & Co, an estimated $69.2M added.
- The largest BridgeBio Pharma seller in Q4 2023 was HHLR Advisors, an estimated $41.8M sold.
Based on aggregated 13F filings for Q4 2023.